Gapping up
In reaction to strong earnings/guidance:
- N/A.
Select metals/mining stocks trading higher:
- DRD +5.9%, SAND +3.7%, CDE +3.4%, HL +3%, AG +2.1%, SLV +1.8%, PAAS +1.7%
Other news:
- AVDL +22.3% (FDA agreement to reduce the sample size for the ongoing pivotal Phase 3 study for once-nightly FT218)
- MNK +16.4% (announces 'positive' top-line results from its pivotal Phase 3 clinical trial of its investigational StrataGraft regenerative tissue)
- PSMT +7.7% (to join S&P SmallCap 600)
- EXAS +6.5% (receives FDA approval for Cologuard for eligible average-risk individuals ages 45 and older)
- GWPH +5.3% (EC has approved the marketing authorisation for EPIDYOLEX )
- VIA +5.2% (acquires rights to Seinfeld)
- TELL +4.4% (MOU with Petronet LNG)
- MDR +2% (continued volatility in pre-mkt)
- OSTK +1.3% (continued volatility in pre-mkt)
- NVO +1.2% (Rybelsus the first GLP-1 in a tablet approved in the US)
- SALT +1.1% (sells two Ultramax vessels)
Analyst comments:
- CHWY +2.9% (upgraded to Buy from Neutral at Nomura)
- AEIS +1.2% (upgraded to Buy from Neutral at Citigroup)